Condensed Consolidated Statements of Operations - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total revenues			$ 130,440	$ 119,371	$ 594,547
Cost of revenues			(110,441)	(119,371)	(520,502)
Gross profit			19,999		74,045
Operating expenses:
Research and development		$ 968,689	826,015	2,564,887	2,535,165
General and administrative		896,547	973,040	3,162,115	3,098,949
Total operating expenses		1,865,236	1,799,055	5,727,002	5,634,114
Loss from operations		(1,865,236)	(1,779,056)	(5,727,002)	(5,560,069)
Other income (expense):
Foreign currency transaction gain (loss)		575	(3,046)	2,257	310
Interest income (expense), net		78,836	66,363	143,603	(97,399)
Research and development incentives			4,729	(25,488)	17,386
CARES Act Employee Retention Credit		66,444	120,771	66,444	120,771
Other income				43	43,223
Loss on extinguishment of debt					(393,791)
Change in fair value of convertible debt			(72,463)	260,933	387,537
Total other income		145,855	116,354	447,792	78,037
Net loss before income taxes		(1,719,381)	(1,662,702)	(5,279,210)	(5,482,032)
Income tax benefit					1,161,197
Net loss applicable to common stockholders		$ (1,719,381)	$ (1,662,702)	$ (5,279,210)	$ (4,320,835)
Basic net loss per share (in Dollars per share)	[1]	$ (0.78)	$ (2.56)	$ (3.84)	$ (10.05)
Diluted net loss per share (in Dollars per share)	[1]	$ (0.78)	$ (2.56)	$ (3.84)	$ (10.05)
Basic weighted average common shares outstanding (in Shares)	[1]	2,203,929	648,860	1,376,568	429,773
Diluted weighted average common shares outstanding (in Shares)	[1]	2,203,929	648,860	1,376,568	429,773
Grant revenue
Total revenues			$ 130,440	$ 119,371	$ 594,547

[1] Adjusted to reflect the reverse stock split of one-for-sixteen effective June 5, 2024